MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

Medicines beginning with S

Sacubitril + Valsartan

Sacubitril 6mg / Valsartan 6mg granules in capsules for opening

No stability information

Stability notes for Sacubitril 6mg / Valsartan 6mg granules in capsules for opening

There are no stability notes for this medicine.

Supplier

Entresto 6mg/6mg granules in capsules for opening (Novartis Pharmaceuticals UK Ltd)

Sacubitril 15mg / Valsartan 16mg granules in capsules for opening

No stability information

Stability notes for Sacubitril 15mg / Valsartan 16mg granules in capsules for opening

There are no stability notes for this medicine.

Supplier

Entresto 15mg/16mg granules in capsules for opening (Novartis Pharmaceuticals UK Ltd)

Sacubitril 24mg / Valsartan 26mg tablets

No stability information

Stability notes for Sacubitril 24mg / Valsartan 26mg tablets

There are no stability notes for this medicine.

Supplier

Entresto 24mg/26mg tablets (Novartis Pharmaceuticals UK Ltd)

Sacubitril 49mg / Valsartan 51mg tablets

No stability information

Stability notes for Sacubitril 49mg / Valsartan 51mg tablets

There are no stability notes for this medicine.

Supplier

Entresto 49mg/51mg tablets (Novartis Pharmaceuticals UK Ltd)

Sacubitril 97mg / Valsartan 103mg tablets

No stability information

Stability notes for Sacubitril 97mg / Valsartan 103mg tablets

There are no stability notes for this medicine.

Supplier

Entresto 97mg/103mg tablets (Novartis Pharmaceuticals UK Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.